NFSG
MRTX

Newbridge Financial Services Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Newbridge Financial Services Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$436 – 1357
2023
Q3 		$436 Hold
10
– – ﹤0.01% 1210
2023
Q2 		$361 Hold
10
– – ﹤0.01% 1270
2023
Q1 		$372 Hold
10
– – ﹤0.01% 1334
2022
Q4 		$453 Hold
10
– – ﹤0.01% 1363
2022
Q3 		$1K Hold
10
– – ﹤0.01% 1362
2022
Q2 		$1K Hold
10
– – ﹤0.01% 1328
2022
Q1 		$1K Hold
10
– – ﹤0.01% 1416
2021
Q4 		$1K Hold
10
– – ﹤0.01% 1386
2021
Q3 		$2K Hold
10
– – ﹤0.01% 1207
2021
Q2 		$2K Hold
10
– – ﹤0.01% 1314
2021
Q1 		$2K Buy
+10
New +$1.98K ﹤0.01% 1215

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Newbridge Financial Services Group's MRTX Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 10 shares — an estimated $436 sold.

Newbridge Financial Services Group first reported a position in MRTX in Q1 2021 and held it in 11 quarters. The position peaked at $2K in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 10 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $436.
  • Newbridge Financial Services Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's Mirati Therapeutics, Inc. Common Stock position peaked at $2K in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.